MannKind Corporation says it will begin to manufacture a 12 unit cartridge strength of Afrezza® (insulin human) inhalation powder to improve glycemic control in adult patients with diabetes.

The 12 unit cartridge was approved by the U.S. Food and Drug Administration on April 17and is expected to be launched by Sanofi in the second half of 2015.